Browsing: openlabel

The phase III FAMILY trial demonstrated a clinically meaningful and statistically significant improvement in PFS with fulvestrant maintenance therapy compared…

BackgroundThe standard first-line therapy for most previously untreated locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) with PD-L1 combined…

BackgroundEndocrine therapy (ET) plus CDK4/6 inhibitor (CDK4/6i) is the mainstay for the management of estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast…

BackgroundDisease progression in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer on first-line endocrine therapy (ET) plus CDK4/6 inhibitor…

BackgroundAdjuvant endocrine therapy (ET) is the standard of care (SOC) for treating estrogen receptor–positive (ER+)/HER2-negative (HER2–) early breast cancer. Despite…

Study design, patient eligibility and treatmentThis was a phase 1, first-in-human, open-label, nonrandomized, dose-escalation study designed to assess the safety,…

de Alava E, Ewing sarcoma, in World Health Organization Classification of Tumours; Pathology and Genetics of Tumours of Soft Tissue…